Skip to main content

Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection

Clinuvel pharmaceuticals

ISIN: AU000000CUV3 , WKN: A0JEGY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


High Growth Tech Stocks To Watch In Australia April 2026

2026-04-27
As the Australian market navigates a soft week with the ASX200 down approximately 2%, local investors are looking to the bullish sentiment from Wall Street, which has recently set new record highs despite global geopolitical tensions. In this climate, identifying high growth tech stocks in Australia involves focusing on companies that demonstrate resilience and adaptability amidst fluctuating economic indicators and broader market sentiments.

CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

2026-04-24
“Totality of evidence” approach to evaluate SCENESSE®EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease assessment tools agreedCUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapyCUV107 study (n=300) to commence in 2H 2026 MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the Euro

ASX Growth Companies With High Insider Ownership April 2026

2026-04-23
As the Australian market navigates a complex landscape marked by geopolitical tensions and fluctuating commodity prices, investors are keeping a close eye on growth companies with high insider ownership. In such an environment, stocks with significant insider stakes can be appealing due to the potential alignment of interests between company leaders and shareholders, offering a sense of confidence amidst global uncertainties.

High Growth Tech Stocks In Australia To Watch

2026-04-23
As Australian shares experience a mixed start to the week, diverging from Wall Street's recent rallies, investors are closely monitoring global events such as tensions in the Strait of Hormuz and fluctuations in Brent crude prices. In this dynamic environment, identifying high growth tech stocks in Australia requires a keen eye on innovation and market adaptability amidst shifting economic indicators.

High Growth Tech Stocks in Australia with Promising Potential

2026-04-19
The Australian market is experiencing a slight dip as investors remain cautious amid uncertainties surrounding potential fuel rationing and the impact of geopolitical tensions on global markets. In this climate, high growth tech stocks in Australia with promising potential are those that demonstrate resilience, innovation, and adaptability to navigate these complex economic conditions.

ASX Growth Companies With High Insider Ownership For April 2026

2026-04-15
As Australian shares continue to climb amid global uncertainties, including ongoing tensions in the Middle East and concerns about fuel shortages, investors are keenly observing how these factors might impact market dynamics. In such a volatile environment, growth companies with high insider ownership often attract attention due to the confidence insiders demonstrate in their business prospects, offering potential resilience and alignment of interests with shareholders.

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

2026-04-15
AAD 2026 reinforces CLINUVEL’s expertise in dermatology Step inside CLINUVEL’s Pavilion of Photomedicine and experience the energy of AAD 2026 through an exclusive video featuring behind-the-scenes of construction, expert insights from the CLINUVEL team and immersive visuals of guests engaging within the Pavilion. MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (A

ASX Growth Stocks With High Insider Ownership And Up To 40% Earnings Growth

2026-04-13
As the Australian market grapples with geopolitical tensions and fluctuating indices, investors are increasingly seeking resilient opportunities amidst the uncertainty. In this environment, growth companies with high insider ownership can offer a compelling proposition, as they often demonstrate strong alignment between management and shareholder interests, potentially driving robust earnings growth even in challenging times.

ASX Growth Companies With High Insider Ownership In April 2026

2026-04-12
As the Australian market remains steady amidst global geopolitical developments, investors are keeping a close eye on growth companies with strong insider ownership that could offer resilience in uncertain times. In such a landscape, firms where insiders hold significant stakes may align their interests closely with shareholders, potentially providing stability and confidence to investors navigating these complex conditions.

ASX Growth Stocks Backed By Insiders

2026-04-09
The Australian stock market is experiencing a mixed phase, with recent gains followed by profit-taking as geopolitical tensions create uncertainty. Amidst this backdrop, growth companies with high insider ownership can be attractive due to the confidence insiders demonstrate in their businesses.